Abstract

1,223 ambulant patients with gonorrhoea were each treated with a single dose of eight tablets of cotrimoxazole. 1,069 patients were followed up (794 males and 275 females). Of these, only 46 (4%) failed to respond. Cotrimoxazole in the dosage used was well tolerated by all the patients, with very few side-effects. There was clear evidence that cotrimoxazole did not mask concomitant syphilitic infections; neither did it produce a gonococcal carrier state. The incidence of post-gonococcal non-specific urethritis was 6 per cent. At present cotrimoxazole seems to be the most useful alternative to penicillin in the treatment of gonorrhoea.